Source-based product analysis. This article contains no Vastkind hands-on test or original product measurements.
Disclosure: This review contains affiliate links. If you purchase via our links, Vastkind may earn a commission at no extra cost to you.
The most useful question about a longevity supplement is what would count as success. A changed laboratory reading? More years without disability? A longer life? Those are different outcomes, and Ca-AKG is a good example of why the distinction matters.
Calcium alpha-ketoglutarate has attracted interest through animal experiments and human studies of DNA methylation, a chemical marking pattern used in some biological-age estimates. The evidence below gives us specific observations to examine. It does not give us a personal longevity prescription.
The animal story has become more complicated
A 2020 mouse study reported longer survival in female mice and reduced frailty in both sexes receiving a Ca-AKG-supplemented diet. That made the compound an interesting experimental candidate. It did not establish a human benefit.
In March 2026, the Interventions Testing Program reported a different result. Its tested AKG regimen did not significantly extend lifespan in genetically heterogeneous UM-HET3 mice of either sex when started at seven months. The authors also discuss an earlier null result with a later start. This was a different mouse population and experimental setup; it is not an exact replay of the original study. It does mean that “extends lifespan in mice” needs a qualification about which experiment.
Our interpretation: reproduction across conditions is part of the evidence, not an optional footnote to the most exciting finding. A supplement assessment should make room for results that complicate its original appeal.
What the human clock studies measured
The widely cited 2021 Rejuvant study retrospectively examined 42 people who had taken a formulation containing Ca-AKG plus vitamins. Their saliva-based DNA-methylation age estimates fell by roughly eight years on average after about seven months. There was no randomized placebo group, and the formulation did not isolate Ca-AKG. The paper disclosed commercial relationships involving the test provider and supplement company.
An eight-year change in that score is not eight additional years of life. The design cannot show what would have happened to the same people without the supplement, and it did not measure a lifespan extension.
A 2026 observational paper examined 4,260 people who had purchased a saliva epigenetic test. Use of delayed-release Ca-AKG plus vitamins was associated with a lower age residual, meaning a lower estimate relative to age. Ordinary AKG did not show the same statistically significant association. In the longitudinal subset, the reported associations did not remain significant after multivariable correction. Healthy-user and recruitment biases remained limitations. The acknowledgments identify an author's advisory and board roles at the company producing Rejuvant. The paper reports associations, not a randomized treatment effect.
Neither paper turns a consumer clock result into a validated instruction for changing supplements. A bigger observational sample can sharpen a question while leaving its causal answer unresolved.
A trial plan is a different kind of evidence
The ABLE protocol describes a placebo-controlled trial of sustained-release Ca-AKG in middle-aged adults selected for an older DNA-methylation age. Its planned outcomes include the clock measure and functional and metabolic assessments. The 2025 recruitment publication evaluates recruitment feasibility; it is not a report demonstrating that treatment improved those outcomes.
For a future result, we would look first for the prespecified comparison between groups, missing data, adverse events, and whether any functional benefit accompanies a clock change. A favorable score alone would still need interpretation.
Reading a product claim without buying its conclusion
Three checks make the evidence more usable:
- Match the formulation. A combination product is not interchangeable with every bottle bearing the ingredient's name.
- Name the outcome. Ask whether the cited work measured survival, function, a biomarker, or an association.
- Keep the comparison. An improvement from baseline can mean something different from an improvement relative to placebo.
These are criteria for judging a claim, not instructions for self-experimentation. The FDA advises discussing supplements with a health professional; a study regimen does not establish a safe personal dose.
Vastkind's assessment is that Ca-AKG remains a research question whose answer depends on the outcome being claimed. Our semaglutide mouse-study analysis shows why even direct survival findings need careful separation from human promises.
Retailer search (affiliate link): Ca-AKG listings. Listings are not evidence of effectiveness or an endorsement of a particular formulation.
Editorial correction, 6 September 2026: We withdrew the earlier safe-dose and broad-benefit claims, rebuilt the article around identified evidence, and added contrasting animal findings and newer observational research. The original publication date and URL have been retained.
This is educational analysis, not individualized medical advice.
